pipeline-prospector-insert-v1
X

Find Oncology Drugs in Phase II Clinical Development in CHINA

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tucidinostat

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Meiji Seika Pharma

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 08, 2020

            Details:

            HUYABIO will complete the development of HBI-8000 for PTCL and ATL in Japan for commercialization by Meiji who will hold exclusive sales and marketing rights.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MOR202,Lenalidomide,Dexamethasone

            Therapeutic Area: Oncology

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 03, 2020

            Details:

            I-Mab initiated two registrational trials with TJ202/MOR202 in relapsed or refractory MM in Taiwan in early 2019 &expanded these trials into mainland China in late 2019, after receiving IND clearance from the (NMPA)